title: Long-term mortality from second malignant neoplasms in 5-year survivors of solid childhood tumors: temporal pattern of risk according to type of treatment.
abstract: BACKGROUND
  The temporal pattern in mortality from late second malignant neoplasms in solid childhood cancer survivors, according to the type of treatment, has not been investigated in detail.
  
  
  METHODS
  We studied 4,230 5-year survivors of solid childhood cancer diagnosed between 1942 and 1986 in France and the United Kingdom. Complete clinical, chemotherapy, and radiotherapy data were recorded and the integral radiation dose was estimated for 2,701 of the 2,948 patients who had received radiotherapy.
  
  
  RESULTS
  After a median follow-up of 28 years, 134 fatal events were due to second malignancies, compared with the 13.3 expected from the general France-UK population rates. The standardized mortality ratio was of a similar magnitude after radiotherapy alone and chemotherapy alone and higher after both treatments. The standardized mortality ratio decreased with follow-up, whereas the absolute excess risk increased significantly over a period of at least 25 years after the first cancer. This temporal pattern was similar after chemotherapy alone, radiotherapy alone, or both treatments. We observed a similar long-term temporal pattern among survivors who had died of a second malignant neoplasm of the gastrointestinal tract and breast. Survivors who had received a higher integral radiation dose during radiotherapy were at a particularly high risk, as well as those who had received alkylating agents and epipodophyllotoxins.
  
  
  CONCLUSIONS
  Five-year survivors of childhood cancer run a high long-term mortality risk for all types of second malignant neoplasms whatever the treatment received and require careful long-term screening well beyond 25 years after the diagnosis.
authors.affiliation: Radiation Epidemiology Group, CESP Centre for research in Epidemiology and Population Health, U1018, Inserm, Villejuif, France.
authors.forename: Markhaba
authors.initials: M
authors.lastname: Tukenova
authors.forename: Ibrahima
authors.initials: I
authors.lastname: Diallo
authors.forename: Mike
authors.initials: M
authors.lastname: Hawkins
authors.forename: Catherine
authors.initials: C
authors.lastname: Guibout
authors.forename: Eric
authors.initials: E
authors.lastname: Quiniou
authors.forename: Hélène
authors.initials: H
authors.lastname: Pacquement
authors.forename: Frederic
authors.initials: F
authors.lastname: Dhermain
authors.forename: Akhtar
authors.initials: A
authors.lastname: Shamsaldin
authors.forename: Odile
authors.initials: O
authors.lastname: Oberlin
authors.forename: Florent
authors.initials: F
authors.lastname: de Vathaire
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D009381:Neoplasms, Radiation-Induced / Q000401:mortality*; D016609:Neoplasms, Second Primary / Q000209:etiology / Q000401:mortality*; D011878:Radiotherapy / Q000009:adverse effects*; D012307:Risk Factors; D017741:Survivors
chemical_list: D000970:Antineoplastic Agents